The European Commission said on Tuesday it had signed a joint procurement contract with Spanish pharmaceutical firm HIPRA for the supply of its protein COVID-19 vaccine, which will be available if approved by the European Medicines Agency (EMA).
Follow Israel Hayom on Facebook, Twitter, and Instagram
The European Union's executive said in a statement that 14 countries are participating in the agreement, under which they can purchase up to 250 million doses.
HIPRA hopes its vaccine, which is under a rolling review by the EMA, will be approved and ready to be administered by the autumn, the Spanish company said in a statement, calling the EU's announcement a "sign of confidence" in its shot.
European Commissioner for Health Stella Kyriakides said in the EU statement that with COVID-19 infections on the rise in Europe, "we need to ensure maximum preparedness as we head into the autumn and winter months".
